Month: February 2018

The Lexington News Issue #2

Dear Lexington Biosciences Shareholders & Friends, I am pleased to provide a continuing overview of recent and future events underway here at Lexington Biosciences. The purpose of these updates is to keep you informed of the progress of the company in regards to our technology, operations, and  nancing. For those of you new to our

Read More

Lexington Begins HeartSentry Clinical Trial

Trial designed to study safety and effectiveness for a non-invasive diagnostic device for cardiovascular health management VANCOUVER, British Columbia, Feb. 20, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce commencement of its clinical trial and first patient enrollment.  These clinical studies are designed to measure

Read More

Lexington Delivers 1st Generation HeartSentry for Clinical Trials

Device completes software, mechanical and electrical tests in preparation for human study VANCOUVER, BRITISH COLUMBIA – February 13, 2018 – Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to advise that its HeartSentry 1st generation product has successfully passed all requisite bench tests in preparation for

Read More



Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News